Antitussive activity and respiratory system effects of levodropropizine in man.
Antitussive activity of the new antitussive drug, levodropropizine (S(-)-3-(4-phenyl-piperazin-1-yl)-propane-1,2-diol, DF 526), was evaluated in healthy volunteers by the classical method of citric acid-induced coughing. Levodropropizine dose-dependently reduced cough frequency. Maximal inhibition was observed at 6 h after administration. Cough intensity was also reduced, as shown by the analysis of cough noise. Levodropropizine, at the dosage of 60 mg t.i.d., had no adverse effects on respiratory function nor on airway clearance mechanisms: in fact, it did not affect spirometric parameters. Levodropropizine had no effects on the rheological properties of mucus nor on ciliary activity of airway epithelium.
Bossi
R
R
Institute of Respiratory Diseases, University of Milan, Italy.
Braga
P C
PC
Centanni
S
S
Legnani
D
D
Moavero
N E
NE
Allegra
L
L
D000328:Adult; D000996:Antitussive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D002923:Cilia / Q000187:drug effects; D003371:Cough / Q000188:drug therapy*; D004848:Epithelium / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012044:Regression Analysis; D012119:Respiration / Q000187:drug effects*; D012137:Respiratory System / Q000187:drug effects
D000996:Antitussive Agents; D011409:Propylene Glycols; C035916:dipropizine